Norris I Hollie1, Eddy S Konaniah1, Colleen Goodin1, David Y Hui2. 1. Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA. 2. Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA. Electronic address: huidy@ucmail.uc.edu.
Abstract
OBJECTIVE: Previous studies have shown that inactivation of the group 1B phospholipase A2 (Pla2g1b) suppresses diet-induced obesity, hyperglycemia, insulin resistance, and hyperlipidemia in C57BL/6 mice. A possible influence of Pla2g1b inactivation on atherosclerosis has not been addressed previously. The current study utilized LDL receptor-deficient (Ldlr(-/-)) mice with plasma lipid levels and distribution similar to hyperlipidemic human subjects as a preclinical animal model to test the effectiveness of Pla2g1b inactivation on atherosclerosis. METHODS AND RESULTS: The Pla2g1b(+/+)Ldlr(-/-) and Pla2g1b(-/-)Ldlr(-/-) mice were fed a low fat chow diet or a hypercaloric diet with 58.5 kcal% fat and 25 kcal% sucrose for 10 weeks. Minimal differences were observed between Pla2g1b(+/+)Ldlr(-/-) and Pla2g1b(-/-)Ldlr(-/-) mice when the animals were maintained on the low fat chow diet. However, when the animals were maintained on the hypercaloric diet, the Pla2g1(+/+)Ldlr(-/-) mice showed the expected body weight gain but the Pla2g1b(-/-)Ldlr(-/-) mice were resistant to diet-induced body weight gain. The Pla2g1b(-/-)Ldlr(-/-) mice also displayed lower fasting glucose, insulin, and plasma lipid levels compared to the Pla2g1b(+/+)Ldlr(-/-) mice, which displayed robust hyperglycemia, hyperinsulinemia, and hyperlipidemia in response to the hypercaloric diet. Importantly, atherosclerotic lesions in the aortic roots were also reduced 7-fold in the Pla2g1b(-/-)Ldlr(-/-) mice. CONCLUSION: The effectiveness of Pla2g1b inactivation to suppress diet-induced body weight gain and reduce diabetes and atherosclerosis in LDL receptor-deficient mice suggests that pharmacological inhibition of Pla2g1b may be a viable strategy to decrease diet-induced obesity and the risk of diabetes and atherosclerosis in humans.
OBJECTIVE: Previous studies have shown that inactivation of the group 1B phospholipase A2 (Pla2g1b) suppresses diet-induced obesity, hyperglycemia, insulin resistance, and hyperlipidemia in C57BL/6 mice. A possible influence of Pla2g1b inactivation on atherosclerosis has not been addressed previously. The current study utilized LDL receptor-deficient (Ldlr(-/-)) mice with plasma lipid levels and distribution similar to hyperlipidemic human subjects as a preclinical animal model to test the effectiveness of Pla2g1b inactivation on atherosclerosis. METHODS AND RESULTS: The Pla2g1b(+/+)Ldlr(-/-) and Pla2g1b(-/-)Ldlr(-/-) mice were fed a low fat chow diet or a hypercaloric diet with 58.5 kcal% fat and 25 kcal% sucrose for 10 weeks. Minimal differences were observed between Pla2g1b(+/+)Ldlr(-/-) and Pla2g1b(-/-)Ldlr(-/-) mice when the animals were maintained on the low fat chow diet. However, when the animals were maintained on the hypercaloric diet, the Pla2g1(+/+)Ldlr(-/-) mice showed the expected body weight gain but the Pla2g1b(-/-)Ldlr(-/-) mice were resistant to diet-induced body weight gain. The Pla2g1b(-/-)Ldlr(-/-) mice also displayed lower fasting glucose, insulin, and plasma lipid levels compared to the Pla2g1b(+/+)Ldlr(-/-) mice, which displayed robust hyperglycemia, hyperinsulinemia, and hyperlipidemia in response to the hypercaloric diet. Importantly, atherosclerotic lesions in the aortic roots were also reduced 7-fold in the Pla2g1b(-/-)Ldlr(-/-) mice. CONCLUSION: The effectiveness of Pla2g1b inactivation to suppress diet-induced body weight gain and reduce diabetes and atherosclerosis in LDL receptor-deficient mice suggests that pharmacological inhibition of Pla2g1b may be a viable strategy to decrease diet-induced obesity and the risk of diabetes and atherosclerosis in humans.
Authors: Scott W Altmann; Harry R Davis; Li-Ji Zhu; Xiaorui Yao; Lizbeth M Hoos; Glen Tetzloff; Sai Prasad N Iyer; Maureen Maguire; Andrei Golovko; Ming Zeng; Luquan Wang; Nicholas Murgolo; Michael P Graziano Journal: Science Date: 2004-02-20 Impact factor: 47.728
Authors: Scott G Wilson; Gail Adam; Maria Langdown; Rikard Reneland; Andreas Braun; Toby Andrew; Gabriela L Surdulescu; Maria Norberg; Frank Dudbridge; Peter W Reed; Philip N Sambrook; Patrick W Kleyn; Tim D Spector Journal: Eur J Hum Genet Date: 2006-03 Impact factor: 4.246
Authors: D Y Hui; M J Cope; E D Labonté; H-T Chang; J Shao; E Goka; A Abousalham; D Charmot; J Buysse Journal: Br J Pharmacol Date: 2009-06-25 Impact factor: 8.739
Authors: Johannes Aufenanger; Michael Samman; Michael Quintel; Klaus Fassbender; Wilma Zimmer; Thomas Bertsch Journal: Clin Chem Lab Med Date: 2002-03 Impact factor: 3.694
Authors: Eric D Labonté; R Jason Kirby; Nicholas M Schildmeyer; April M Cannon; Kevin W Huggins; David Y Hui Journal: Diabetes Date: 2006-04 Impact factor: 9.461
Authors: Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman Journal: J Lipid Res Date: 2015-02-02 Impact factor: 5.922
Authors: Arnab Chattopadhyay; Mohamad Navab; Greg Hough; Victor Grijalva; Pallavi Mukherjee; Hannah R Fogelman; Lin H Hwang; Kym F Faull; Aldons J Lusis; Srinivasa T Reddy; Alan M Fogelman Journal: J Lipid Res Date: 2016-03-09 Impact factor: 5.922
Authors: Michael S Kuefner; Kevin Pham; Jeanna R Redd; Erin J Stephenson; Innocence Harvey; Xiong Deng; Dave Bridges; Eric Boilard; Marshall B Elam; Edwards A Park Journal: J Lipid Res Date: 2017-06-29 Impact factor: 5.922